Oral sodium butyrate impacts brain metabolism and hippocampal neurogenesis, with limited effects on gut anatomy and function in pigs

To cite this version:
David Val-Laillet, Sylvie Guerin, Nicolas Coquery, Isabelle Nogret, Michele Formal, et al.. Oral sodium butyrate impacts brain metabolism and hippocampal neurogenesis, with limited effects on gut anatomy and function in pigs. FASEB Journal, 2018, 32 (4), pp.2160-2171. 10.1096/fj.201700547RR . hal-01771621

HAL Id: hal-01771621
https://univ-rennes.hal.science/hal-01771621
Submitted on 6 Jul 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Oral sodium butyrate impacts brain metabolism and hippocampal neurogenesis, with limited effects on gut anatomy and function in pigs

David Val-Laïllet¹,⁵,* , Sylvie Guérin¹, Nicolas Coquery¹, Isabelle Nogret¹, Michèle Formal¹, Véronique Romé¹, Laurence Le Normand¹, Paul Meurice¹, Gwénaëlle Randuineau¹, Paul Guilloteau¹, Charles-Henri Malbert², Patricia Parnet³,⁴,⁵, Jean-Paul Lallès¹,⁵, Jean-Pierre Segain³,⁴,⁵

¹ INRA, INSERM, Univ Rennes, UBL, Nutrition Metabolisms and Cancer, NuMeCan, Rennes, France
² INRA, US1395 Ani-Scans, St Gilles, France
³ INRA UMR 1280 INRA-Université de Nantes, Physiologie des Adaptations Nutritionnelles, PhAN, Nantes, France
⁴ Institut des Maladies de l’Appareil Digestif (IMAD), CHU Hôtel-Dieu, Nantes, France
⁵ Centre de Recherche en Nutrition Humaine Ouest (CRNHO), Nantes, France.

Short title: Effect of oral butyrate on pig brain

* Corresponding author: David Val-Laïllet, INRA 1341 NuMeCan, F-35590 St Gilles, France. david.val-laillet@inra.fr

Authors contribution: DVL, CHM, JPL, PG, PP and JPS designed the research and secured funding; DVL, SG, IN, JPL and PG performed the animal experiments; DVL, SG and CHM
performed brain imaging or provided analytical strategies; DVL, NC, SG and GR performed brain post-mortem analyses; MF, VR, LLN, PG and JPL performed gut measurements, blood and pancreas analyses; DVL, NC, PM, and JPL performed the statistical analyses; DVL wrote the paper; and all co-authors read and revised the paper.
Abbreviations

CA-CP: commissura anterior-commissura posterior
CGM: cerebral glucose metabolism
CTI: computed tomography imaging
DCX: doublecortin
FDG: fluorodeoxyglucose
GCL: granular cell layer
PET: positron emission tomography
rCGM: regional cerebral glucose metabolism
ROI: region of interest
SGZ: sub-granular zone
SPM: statistical parametric mapping
SVC: small volume correction
Abstract

Butyrate can improve gut functions while HDAC inhibitors might alleviate neurocognitive alterations. Our aim was to assess whether oral butyrate could modulate brain metabolism and plasticity and if this would relate to gut function. Sixteen pigs were subjected to sodium butyrate (SB) supplementation via beverage water or water only (C). All pigs had blood sampled after 2 and 3 weeks of treatment, and were subjected to a brain positron emission tomography after 3 weeks. Animals were euthanized after 4 weeks to sample pancreas, intestine, and brain for gut physiology and anatomy measurements, as well as hippocampal histology, Ki67 and DCX immunohistochemistry. SB compared to C treatment triggered basal brain glucose metabolism changes in the nucleus accumbens and hippocampus ($P = 0.003$), increased hippocampal GCL volume ($P = 0.006$) and neurogenesis (Ki67: $P = 0.026$; DCX: $P = 0.029$). After 2 weeks of treatment, plasma levels of glucose, insulin, lactate, GLP-1 and PYY remained unchanged. After 3 weeks, plasma levels of lactate were lower in SB compared to C animals ($P = 0.028$), with no difference for glucose and insulin. Butyrate intake impacted very little gut anatomy and function. These results demonstrate that oral SB impacted brain functions with little effects on the gut.

Keywords: sodium butyrate, pancreas, gut, brain metabolism, cognition, hippocampus
Brain and behavior alterations are observed in various pathologies including anxiety, depression, Parkinson’s or Alzheimer diseases, and are also suspected to operate in diet-dependent metabolic disorders and obesity (1, 2). Histone deacetylase (HDAC) inhibitors such as butyrate have been repeatedly shown to prevent or even treat alterations in brain functions (e.g. memory) and behavioral disorders in various rodent models of diseases like stress-induced anxiety (3) or Parkinson (4). Underlying mechanisms most often involve factors entailed in brain neurogenesis and synapse plasticity, including brain- and glial cell line-derived neurotrophic factors and nerve growth factor (3, 4). Interestingly, HDAC have a memory-suppressant effect that can be neutralized by HDAC inhibitors such as butyrate (5-7). In addition, long-term memory processes depend on H3 histone acetylation at the hippocampus level, which is favored by butyrate (5, 7, 8). However, butyrate could also prevent memory impairment and improve cognition through the upregulation of neurotrophic factors (3, 9). Butyrate also functions as a ligand for a subset of G protein-coupled receptors and as an energy metabolite (10).

Butyrate is a short-chain fatty acid naturally produced in the gut through bacterial fermentation of dietary fibers that plays an essential role in gastrointestinal tract functions. Butyrate is the primary energy source for colonocytes through mitochondrial β-oxidation and, as already mentioned, modulates gene expression through HDAC inhibition. Dietary butyrate enhanced growth rate and improved feed conversion rate before and during weaning in calves (11, 12) and in piglets (13, 14). Different studies performed in piglets or calves showed that butyrate also delayed gastric emptying (15, 16), increased the density of gastric parietal cells (17) and colonic goblet cells (18), enhanced HSP27 and HSP70 expression in the stomach and
colon (12), and increased the activities of many brush-border enzymes in the small intestine (12). Bioactive peptides or hormones secreted into the blood and/or locally produced in the gastrointestinal tract were suggested to be responsible for butyrate effects on gastrointestinal tract development. Altogether, these results are in favor of an effect of butyrate supplementation on the gastrointestinal tract development in mammals especially as butyrate is ingested soon after birth (19).

Whether dietary butyrate can modulate brain functions and metabolic activity in physiological situation is poorly documented. A large body of evidence suggests that butyrate can be absorbed from the gut and entirely metabolized either in the gut mucosa or in the liver, which makes it very difficult to detect butyrate in systemic blood circulation (18). But butyrate is known to cross the blood-brain barrier and to affect epigenetic machineries in the brain (20). Accordingly, monocarboxylate transporters (MCTs) that mediate the transport of monocarboxylates such as lactate, pyruvate, short-chain fatty acids and ketone bodies (21) are present in the blood-brain barrier, glial cells and neurons. Although glucose is the major fuel for normal, activated brain at the adult age (22), it is well established that ketones such as β-hydroxybutyrate and acetoacetate are alternative energy substrates during suckling, starvation or fasting periods and in situations of ketosis induced by high-fat diet (23-25). Several human and animal studies using 18F-fluorodeoxyglucose (FDG) and positron emission tomography (PET) provided evidence that cerebral metabolism of glucose is reduced during ketosis (25-27). However, it is not known whether butyrate, produced in the gastrointestinal tract and present at low levels (µM) in blood, can modulate regional brain glucose metabolism.

The aim of the present study was to test the hypothesis that oral sodium butyrate supplementation modulates brain metabolic activity and hippocampal structural plasticity, and that part of this modulation stems in the effects of butyrate on gut biology and barrier
function. We tested this hypothesis in growing pigs as we developed brain imaging in this species for investigating diet-induced brain and behavior modulations (2, 28, 29). The pig is now recognized as a valuable alternative model to rodents for investigating human nutrition, gastrointestinal tract development and gut-brain axis interplay (19, 30). Besides, butyrate supplementation was shown to improve development of gastrointestinal tract anatomy and functions in young mammals (13, 31). Exploring different pancreatic and intestinal parameters might contribute to identify potential gut-brain communication pathways for the putative effects of oral butyrate supplementation on brain biology.

2. Materials & Methods

The present experiment was conducted in accordance with the current ethical standards of the European Community (Directive 2010/63/EU), agreement No. A35-622 for the experimental facilities, and authorization No. 35-88 to experiment on live animals for the principal investigator of the study. The Regional Ethics Committee in Animal Experiment of Brittany (France) validated the entire procedure described in this paper (R-2012-DVL-01).

Animals and housing

Four successive batches of four Large White/Landrace × Piétrain 2.5-month-old female growing pigs of 28.9 ± 1.2 kg (mean ± SEM) body weight (BW) at the beginning of the study were used. The piglets were weaned at 28 days of age and subsequently housed in individual pens (length 80 × width 60 × height 68 cm) equipped with a feeding trough and a drinking nipple. The room temperature was kept at 23.4 ± 0.1°C with a 13:11-h light-dark cycle.

Diet and experimental beverages
The pigs were fed a pelleted pre-starter diet from weaning (day 1) to 15 days after weaning and then a starter diet until the end of the study (at approximately 3.5 months after birth). The diets were formulated so that the nutrient composition (other than total sulfur amino acids) met or exceeded recommendations of the NRC (1998) throughout the experimental period (see 32 for the composition of the diets). Animals were divided into two experimental groups. Sodium Butyrate group, SB: 28.7 ± 0.9 kg; Control group, C: 29.2 ± 0.9 kg), with two animals per group in each batch (n = 8 animals per group in total), and were weighed weekly. During the whole experiment, all the pigs received 40 g of feed per kg BW, which corresponds to the usual allowance in the pig facilities. Ad libitum feeding was not used in this study to limit feed intake variability across individuals and to prevent feed refusals. Indeed, the amount of butyrate supplied to the SB pigs was based on the amount of feed ingested. The daily feed allowance was distributed once a day at 0930 h. One hour before meal provision, at 0830 h, the animals received either water alone (control, C group) or a 10-mM sodium butyrate solution (SB group). Access to tap water was permitted only once the amount of water or butyrate solution was completely consumed, and was then presented again in the mid-afternoon until the next day. The present dosage of butyrate (110 mg/kg BW/day) is within the physiological range used in other studies with pigs (13, 31) and rodents (33, 34). Control animals received only tap water.

**Surgical implantation of jugular catheter**

Animals were fitted with a jugular catheter under general anaesthesia performed as previously described (35) to achieve 2.2 Minimum Alveolar Concentration (MAC) for isoflurane. Analgesia was achieved with an additional infusion of Fentanyl (30 to 100 µg/kg/hr IV, Renaudin, Paris, France) during surgery. A silicon catheter was introduced into the external jugular vein and tunnelled subcutaneously to exit in the interscapular space.
Animals were allowed to recover for one week after the surgical procedure before any observation or treatment was made.

**Blood sampling and analyses**

All the jugular blood samples were collected in tubes (10 ml) containing ethylene diamine tetraacetate (EDTA) (VT-100 STK, 0.1 ml EDTA, 0.47 ml/l: 21 w/v %, CML, Nemours, France). Moreover, a protease inhibitor cocktail (ref P2714-1BTL, SIGMA, L’isle d’Abeau Chenes, Saint-Quentin Fallavier, France) was added to tubes aimed at GLP-1 assays. Two weeks after the beginning of treatments, samples were collected just before (0830 h) the distribution of the experimental treatments (tap water alone for the C group, sodium butyrate solution for the SB group) and 1h after (0930 h), *i.e.* just before feeding (for lactate, insulin, peptide YY – PYY, GLP-1 and osmolality measurements). Three weeks after the beginning of the treatments, other samples were also collected in anaesthetized animals just before brain imaging (for glucose, lactate and insulin measurements). All blood samples were kept in ice before plasma preparation by centrifugation (2300 x g, 10 min, + 4°C). Plasma was recovered, aliquoted and stored frozen at - 40°C until analysis.

Plasma concentrations of GLP-1 (pM) were measured by means of a commercial Glucagon Like Peptide-1 (Active)Elisa Immuno Assay Kit (ref. EGLP-35 K, Merck KGaA, Darmstadt, Germany). Peptide YY plasma concentrations (ng/ml) were determined using a commercial PYY Elisa Immuno Assay Kit (ref. EK-059-04, Phœnix Pharmaceuticals, INC., , Burlingame, CA 0, USA). Insulin concentration was measured by RIA (Insulin-CT; CisbioBioassays, Codolet, France). Plasma levels of glucose and lactate were measured in duplicate by automated spectrophotometry (Konelab 20i; Thermo Fisher Scientific, Waltham, MA, USA). Plasma osmolality was measured on a micro-osmometer (Hermann Roebling 12/12 DR, Berlin, Germany).

**Brain imaging procedure**
After three weeks of treatment, the animals underwent a brain-imaging session to investigate basal brain metabolism. The brain imaging modality used to investigate the regional cerebral glucose metabolism (rCGM) was the positron emission tomography (PET) of $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG, CIS bio international, France). The procedure for animal preparation and anesthesia was similar to that described in our previous publications (36, 37). The animals were placed in a head first supine position on the bed of a whole body, high-resolution PET. A venous catheter was then inserted into their left ear in order to inject the $^{18}$fluoro-deoxyglucose radiolabel ($^{18}$F-FDG, 200 MBq in 20 ml), at least 30 min after the beginning of anesthesia. Brain images were acquired on a computed tomography imaging machine in 3D mode (CTI/Siemens ECAT, 962, HR+) and processed as described in Clouard et al. (36).

**Euthanasia, organ and tissue collection**

After four weeks of treatment, the pigs were euthanized with intravenous administration of T61® following a pre-anesthesia with ketamine (5 mg/kg intramuscularly, Rhône Mérieux, Lyon, France), and then exsanguinated.

**Brain collection, fixation and conservation.** After euthanasia, the pigs were decapitated and the head was perfused via the carotids with 2 L of 1% sodium nitrite and 5 L of buffered 4% formalin at 4°C. The brains were kept in buffered 4% formalin during 24 h and then transferred in 30% sucrose with 0.1% sodium azide at 4°C until being sliced with a cryomicrotome. Brain slices were deposited on glass slides and stored at -20°C.

**Gut tissue collection.** Two pigs per afternoon (one C and one SB) were randomly slaughtered at 30 min intervals, 2.5 h after the last treatment (tap water vs. sodium butyrate solution, but no meal). After laparotomy, the entire gastrointestinal tract was carefully removed and the small intestine was isolated by ligation before removal. The pancreas was
weighed and three pieces (about one g per sample) were gently collected, frozen in liquid nitrogen and then stored at -20°C until enzyme activity analysis. The mesentery was removed all along the small intestine that was then measured. Twenty five-centimeter segments of duodenum (20 cm distal to Treitz ligament), mid-jejunum and distal ileum (ending 10 cm proximal to the ileo-cecal valvula) were cut, emptied of digesta contents and gently rinsed with cold saline. For each collected segment, cross-sectional tissue samples were made for the following preparations or analysis: 15 cm for immediate use in Ussing chambers (not duodenum) and quickly transported to the laboratory in cold Ringer bicarbonate solution (see below); 5 cm for fixation (in buffered formalin 10%), paraffin embedding and histology; and 1 cm of whole tissue (cut in small pieces) for HSP analysis was snap-frozen in liquid nitrogen and then stored at -80°C. Part of the remaining collected tissues was scraped using a glass slide (small intestine, 4-5 cm) or cut into small pieces (colon, 1 cm) for enzyme determination, snap-frozen and then stored at -20°C.

**Brain immunohistochemical analysis**

Brain immunohisto-fluorescence was performed on 30-µm brain sections of the left hippocampus. One section every 25 sections was selected for antigen Ki67 and doublecortin (DCX) immunohistochemistry. Only the first 10 selected sections were gathered and used for immunohistochemistry, which covers approximately half of the hippocampus, *i.e.* 7.5 mm over around 15 mm (see 38 for comparison with whole hippocampus sampling). Ki67 and DCX staining was performed on adjacent sections for each hippocampal progression site. Ki67 protein is expressed in proliferating cells while DCX is a microtubule-associated protein expressed by neuronal precursor cells and immature neurons (39).

Sections were thawed during 10 min at room temperature and washed three times for 10 min in phosphate buffered saline (PBS). After the last wash, 150 µL of blocking buffer
PBS solution, Gibco by Life Technologies; 10% horse serum, Sigma; 0.3% Triton, Sigma) was then dropped on the region of interest (ROI) and incubated during 1 h at room temperature in a humidity chamber. Blocking buffer excess was carefully removed with absorbent tissue and 150 µL of primary antibody (Ki67: Anti-Ki67 antibody ab15580, dilution 1:200, Abcam; DCX: Anti-doublecortin (C-18) antibody sc8066 1:200, Santa Cruz) was added on the ROI. Parafilm was carefully laid on tissue slice and slides were stored at 4°C for at least 16 h until the next morning. Sections were then washed three times with blocking buffer for 10 min and 150 µL of secondary antibody (Ki67: Alexa Fluor 488 Conjugate 1/200, Cell Signaling Technology; DCX: Cy3-conjugated AffiniPure Donkey Anti-Goat IgG (H+L) 1:500, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) was added for a 2-h incubation at room temperature. Slides were finally mounted with Fluoroshield Mounting Medium with 4',6-diamidino-2-phenylindole (2 drops per slide, ref 17513, Abcam, Cambridge, UK). Sections were examined under a fluorescent microscope (Eclipse 80i, Nikon), digitized and large-field mosaics were performed with micro-manager (ImageJ plugin) in order to get the whole hippocampal section on one image.

Determination of hippocampus and granular cell layer (GCL) volumes, number of Ki67-positive nuclei in the sub-granular zone (SGZ), number of DCX-positive cells in the GCL were performed for each selected hippocampal section and reported as an inferred value per site considering that each site is a block of 25 sections.

Gut physiology measurements ex vivo (Ussing chambers)

Electrophysiology ex vivo. Six Ussing chambers (2 per gut site; P2250 model; Physiological Instruments, San Diego, CA, USA) were used for investigating gut electrophysiology (and permeability, see below) in each pig. Jejunal, ileal and colonic mucosae were stripped off the muscular layers, cut into two adjacent pieces and immediately
mounted in chambers (1 cm² mucosa in contact with 2.5 ml Ringer bicarbonate buffers). Gut electrophysiology (and permeability) parameters in basal conditions were measured in the two chambers and values averaged per tissue. Then, one chamber was kept in basal condition while the other was used for measurements under oxidative stress using monochloramine (final concentration 1 mM, both sides of the tissue) (40). The Ringer-bicarbonate buffer contained 16 mmol/L of glucose and 16 mmol/L of mannitol on the serosal and mucosal sides, respectively. Chambers were kept at 39°C and buffers oxygenated all the time automatically. Tissue viability was checked every 30 min by recording tissue electrical potential difference automatically. Gut mucosae were left equilibrating for 20 min before short-circuit current (Isc) and the trans-epithelial electrical resistance (TEER) were determined under clamp condition (3 mV for 300 ms every 30 s) using Ohm’s law (41).

Colonic mucosa sodium-dependent glucose absorption capacity and chloride secretion capacity were determined after addition of D-glucose (16 mM, mucosal side) and the cholinergic agonist carbachol (1 mM, serosal side), respectively (41).

Trans- and para-cellular permeability ex vivo. Gut mucosa permeability to FITC-dextran 4000 (FD4, MW 4 kDa; para-cellular permeability marker) and horseradish peroxidase (HRP type II, MW 40 kDa; trans-cellular permeability probe) was assessed exactly as previously described for the small intestine and the colon (42, 43). When tissue electrophysiology was stabilized (see above), FD4 and HRP were added to the mucosal side of tissues and serosal fluid (200 µL, replaced by 200 µL Ringer-glucose) was collected kinetically (every 30 min for 120 min). Fluid FD4 and HRP concentrations were determined by fluorimetry and spectrophotometry, respectively and marker transmucosal flows were calculated as detailed previously (44).

Gut anatomy, enzyme activities and heat shock proteins (HSP)
**Intestinal length and villous-crypt architecture.** Small intestinal length was measured, pieces of tissues were collected at various sites along the gut (see above) and were dehydrated and then embedded in paraffin as reported previously (42, 43). Five-micrometer tissue sections were prepared, dewaxed, rehydrated and stained with eosin and haematoxylin, and villi and crypts (10–15 per section, well oriented, full size) were measured for their length, width and surface area (42, 43). Intestinal villus height-to-crypt depth (VH:CD) ratio, and ‘M’ ratio for estimating three-dimension mucosal surface area (45) were also calculated. Villous and crypt morphology parameters were averaged per site per pig before statistical analysis.

**Pancreatic and intestinal enzyme activities.** After thawing, the samples coming from pancreas tissue and intestinal mucosa, protein content was measured and three pancreatic enzymes (trypsin, E.C. 2.3.21.4; lipase, E.C. 3.1.1.3; amylase, E.C. 3.2.1.1.) were analyzed as reported before (46). The activities of five enzymes – two peptidases (amino-peptidase N, E.C. 3.4.11.2; dipeptidyl-peptidase IV, DPP4, E.C. 3.4.14.5), two disaccharidases (sucrase, E.C. 3.2.1.48; maltase, E.C. 3.2.1.20) and one phosphatase (intestinal alkaline phosphatase, E.C. 3.1.3.1) – were determined in small intestinal mucosa homogenates as previously reported (42, 43). Alkaline phosphatase activity was also determined in a piece of tissue from proximal colon. Specific (/g protein) and total (/kg of BW for pancreas, and /g fresh mucosa for intestine) enzymes activities (or activity concentrations for intestinal alkaline phosphatase) were calculated as previously reported.

**Gut heat shock proteins.** Inducible heat shock proteins HSP27 and HSP70 were determined in gut tissues as reported before (42, 43).

**Statistical analysis**

**Statistical analysis of body weight, pancreatic enzymes and blood plasma data.** Data were tested for normal distribution and homogeneity of variances. Pancreatic enzymes and
blood plasma data were analyzed with a simple ANOVA or an ANOVA for repeated measurements over time to compare data obtained before and after water vs. butyrate intake. Interactions between treatment and time were also investigated (SPSS Statistics software version 20.0; IBM, Somers, NY, USA). All data are reported as means ± SEMs. The level of significance for all analyses was set as \( P < 0.05 \) and trends were considered at \( 0.05 \leq P \leq 0.1 \).

**Brain immunodetection data.** For the immunohistochemistry data, animal numbers are N=7 for Control group (C) and N=6 animals for Butyrate group (SB). Two animals (1 C and 1 SB) were excluded because of an incorrect slicing axis or unsuccessful immunohistochemistry, respectively. Hippocampal site-based statistical analyses were performed with an ANOVA (SPSS Statistics software version 20.0; IBM, Somers, NY, USA), with hippocampal site progression and animal as covariates. Data are presented as mean values for the entire block of 25 slices for each hippocampal site.

**Statistical brain image analysis.** The regional \(^{18}\text{F}-\text{FDG}\) uptake was standardized to the brain global uptake using proportional scaling in order to suppress individual differences in global cerebral glucose metabolism (CGM). Brain images were analyzed using independent \( t \) tests to compare the Butyrate (SB) and Control (C) groups with the two following contrasts: SB > C and SB < C. After a whole-brain first-level analysis without *a priori*, we performed small volume correction (SVC) analyses on ROIs, upon *a priori* hypotheses, *i.e.* in areas associated with learning and memory, attentional processes, reward and cognitive control (anterior prefrontal cortex, dorsolateral prefrontal cortex, orbitofrontal cortex, cingulate cortex, hippocampus, parahippocampal cortex, amygdala, caudate, putamen, nucleus accumbens, globus pallidus). With this analysis, allowing for voxel-to-voxel comparisons within restricted ROIs, we managed to identify the voxels for which the activity was statistically different between groups (treatments) in the ROIs. For the SVC analyses, the
value of $P = 0.05$ (uncorrected for multiple comparisons) was set as the significance threshold with a cluster size $k \geq 25$ voxels. The statistical analysis with Statistical Parametric Mapping 8 (SPM8) produced a listing of voxels for which the activation differed between treatments. Each voxel was associated with a set of coordinates $(x \ y \ z)$ corresponding to its spatial location in the commissura anterior-commissura posterior (CA-CP) plane with CP set as the origin. The ROIs chosen for the SVC analysis were anatomically identified on the basis of a 3D digitized pig brain atlas developed in our laboratory (47).

**Statistical analysis of intestinal parameters.** Intestinal parameter data were analyzed using the Statistical Analyzing System (version 8.1, 2000; SAS Institute Inc., Cary, NC) using models that included the treatment (C vs. SB) the site and the treatment by site interaction. MIXED procedures with REPEATED statement for gut sites were used. Results are presented as least-square means and pooled SEM. Least-square means comparisons for each combination of treatment and site were made only when a tendency ($P \leq 0.10$) for a treatment by site interaction was observed. In these cases, means were separated using Bonferroni post-hoc comparison test. Permeability data displaying non-Gaussian distribution were log-transformed before statistical analysis. Effects were considered significant at $P < 0.05$ and as trends at $0.05 \leq P \leq 0.10$.

3. Results

**Body weight and blood analyses**

During the whole experiment, there was no significant difference in BW between groups (from 29.2 ± 0.9 to 42.0 ± 1.0 kg in C pigs, from 28.7 ± 0.9 to 41.9 ± 1.5 kg in SB
animals, from $P = 0.494$ to $P = 0.949$). All the pigs consumed their daily ration and there was no difference in feed consumption between groups.

**Blood analyses before and after drinking (after two weeks of treatment).** Lactate (Fig 1A), PYY (Fig 1B) and GLP-1 (Fig 1C) jugular plasma levels significantly decreased after drinking, independently from the treatment (lactate, from $922 \pm 93$ to $695 \pm 48$ µmol/l, $P = 0.040$; PYY, from $2.9 \pm 0.2$ to $2.7 \pm 0.2$ ng/ml, $P = 0.0140$; GLP-1, from $14.4 \pm 1.8$ to $13.4 \pm 1.7$ pM, $P = 0.023$). There was an interaction between treatment and time ($P = 0.025$) for osmolality that increased in SB pigs and decreased in C pigs after beverage drinking (Fig 1D). There were no other effects for these four parameters. No effect of the treatment or sampling time nor interaction was observed for plasma glucose and insulin (data not shown).

**Blood analyses before brain imaging (after three weeks of treatment).** SB pigs had lower lactate jugular plasma levels than C pigs ($782 \pm 52$ vs. $1087 \pm 114$ µmol/l; $P = 0.028$) (Fig 1E). There was no difference between groups for the glucose and insulin jugular plasma levels (data not shown).

**Regional brain glucose metabolism**

The without *a priori* analysis revealed very few structures with basal activity differing between groups (Table 1). The right hippocampus ($P = 0.003$), the right primary somatosensory cortex ($P < 0.001$) and left inferior colliculus ($P = 0.002$) were more activated in the SB group than in the C group. The left primary somatosensory cortex ($P = 0.002$) and the left inferior temporal gyrus ($P = 0.004$) were less activated in the SB group than in the C group.

The SVC analysis identified only two brain structures over 14 (bilaterally) selected for which the regional glucose metabolism was different between groups (Table 1). The right
nucleus accumbens was less activated in the SB group than in the C group ($P = 0.010$), while both activated ($P = 0.003$) and deactivated ($P = 0.010$) clusters were found in the right hippocampus in the SB group compared to C group.

Fig 2 indicates the activated and deactivated clusters for the image contrast analyses comparing the SB group to C group.

**Hippocampal structural plasticity**

Hippocampal and GCL volumes increased along the hippocampus site progression (Fig 3). Along hippocampal progression, similar hippocampal volume was measured, whereas the GCL volume was significantly higher in the SB group (Fig 3B, $P = 0.006$).

Ki67-positive nuclei and DCX-positive cells were detected in order to assess the structural plasticity of the hippocampus. Both Ki67-positive nuclei density and DCX-positive cells density appeared higher in the SB group compared to C group (Fig 4A). Along hippocampal site progression, significantly higher numbers of Ki67-positive nuclei and DCX-positive cells were noticed in the SB group as compared to C group (Fig 4B; Ki67: $P = 0.026$; DCX: $P = 0.029$).

**Gut physiology ex vivo (Ussing chambers)**

*Electrophysiology ex vivo.* Mucosal electrophysiology parameters were determined in both basal and oxidant stress conditions (Table 2). Basal Isc did not display any significant treatment by site interaction, or treatment or site effect. Basal glucose absorption capacity (dIsc-glucose) displayed a significant treatment by site interaction ($P = 0.04$), but no treatment or site effect. The interaction and site effects were not significant for chloride secretion capacity (dIsc-carbachol) but treatment effect in basal condition tended to be significant (SB < C, $P = 0.09$) for this variable.
Trans- and para-cellular permeability ex vivo. There was no significant treatment by site interaction for both permeability markers and measurement conditions (Table 3). However, HRP (trans-cellular) permeability in basal condition tended to be globally lower in SB compared to C treatment ($P = 0.09$). Treatment differences for FD4 (para-cellular permeability) in basal or stress condition did not reach significance (Table 3).

**Gut anatomy, enzyme activities and heat shock proteins (HSP)**

**Intestinal length and villous-crypt architecture.** Small intestinal length did not differ between C and SB groups (respectively 0.34 and 0.35 m/kg BW, SEM = 0.042; $P=0.620$). Similarly, there was no significant treatment by site interaction or significant difference between treatments for all parameters of villous-crypt (small intestine), crypt (colon) architecture, villous height-to-crypt depth ratio or M factor (Table S1, Supplemental Material). By contrast, and as expected, site effects were (highly) significant for all the studied variables, except villous perimeter and crypt depth (Table S1).

**Pancreatic and intestinal enzyme activities.** No effect of butyrate ingestion was shown concerning pancreas and intestine protein contents as well as pancreatic enzyme activity levels (Table 4). There was a tendency ($P = 0.063$) for a treatment by site interaction for amino-peptidase N, showing that this enzyme total activity was lower in SB than C group in the jejunum ($P < 0.05$), with no differences in the duodenum or ileum. There was a tendency ($P = 0.07$) for a treatment by site interaction for DPP4 specific activity, though without significant differences at any site. There was no significant treatment by site interaction or treatment differences for disaccharidases and intestinal alkaline phosphatase activities (Table 5). Site effect was highly significant ($P < 0.0001$) for all the analyzed intestinal enzymes.

**Gut Heat shock proteins.** Inducible HSP27 and HSP70 were assayed using Western blotting in gut tissues. There was no significant treatment by site interaction or treatment
differences for these HSPs (Table S2, Supplemental Material). Site effect was (HSP27, 
\( P < 0.0001 \)) or tended to be (HSP70, \( P = 0.07 \)) significant.

4. Discussion

The main result of this study is that butyrate supplementation via beverage water during 3-4 
weeks in growing pigs fed a standard diet can trigger regional brain glucose metabolism 
changes in several brain structures, including the hippocampus. An increased glucose 
metabolism relative to overall brain metabolism was detected in the right hippocampus with 
the first-level analysis and then confirmed with the SVC analysis. This second-level analysis 
performed on specific regions of interest also detected deactivated clusters in the right 
hippocampus and nucleus accumbens. Increased hippocampal plasticity was also detected in 
post-mortem histochemical analyses, with more neurogenesis and an increased GCL volume. 
Blood analyses revealed lower plasma levels of lactate in the SB group compared to the C 
group at the moment of brain imaging, but no difference in terms of glucose or insulin levels. 
This result demonstrates that the differences in basal brain activity observed between groups 
were not attributable to modifications in plasma glycaemia at the time of brain imaging. 
Incidentally, there was no short-term effect of butyrate intake on lactate, glucose, PYY, GLP- 
1 and insulin plasma levels either, indicating that the butyrate effect on regional brain 
metabolism, perceivable at a distance from butyrate ingestion, was not related to systemic 
glucose control or gut hormones variations. The absence of treatment effect for GLP-1 and 
PYY plasma levels was quite surprising because butyrate is known to stimulate the release of 
GLP-1 from intestinal L-cells (48) and increase fasting and postprandial plasma PYY 
concentrations when infused in the colon (49). GLP-1 can improve learning and memory via
an action at the hippocampal level (50), but this mechanism was probably not at the origin of
the effects observed in our study. It is also possible that butyrate never reached L-cells and
was absorbed at the stomach level, which would prevent any significant increase of plasma
GLP-1. In this case, the gut-brain communication pathway involved needs further
investigation.

Our results showed that chronic butyrate supplementation led to a decreased regional
glucose metabolism in the dorsal hippocampus and nucleus accumbens, as well as an
increased regional glucose metabolism in the ventral hippocampus, together with an increased
GCL volume and hippocampal neurogenesis. These data suggest that butyrate, which is
largely metabolized by the gut and the liver, and thus found at very low concentrations (µM)
(18), may influence brain glucose metabolism. It was previously shown in a rat model of
spreading depression, that $^{14}$C-labelled butyrate, injected intravenously, was readily taken up
and metabolized by adult brain, probably by astrocytes (20). Moreover, this study showed that
enhanced cortical butyrate uptake parallels local increase in $^{14}$C-deoxyglucose utilization (20).
However, the increased glucose metabolism found in some brain regions of the SB groups is
in contrast with its reduction generally observed under ketogenic diets (26, 27, 51). The
reduction of brain glucose (oxidative) metabolism during ketosis correlates with the increase
in plasma ketones (acetoacetate and β-hydroxybutyrate) concentration (mM), and is
associated with the increase of cerebral metabolic rate of ketones (26, 27, 51). It has been
proposed that the tricarboxylic acid cycle (TCA) is fed by acetyl-CoA derived from ketones
thereby decreasing glucose oxidation downstream pyruvate dehydrogenase (PDH) (51).
However, concerning butyrate, there is no evidence for such a metabolic behaviour in brain
cells. One explanation for the discrepancy in our observation of a stimulation of glucose
metabolism could be that, in comparison to the high concentration of ketones supplying the
brain, butyrate brain levels may be too low to compete with glucose oxidation. Alternatively,
butyrate-stimulated brain glucose metabolism could implicate the ability of butyrate to act as an HDAC inhibitor, thereby upregulating the transcription of genes involved in glucose metabolic pathway. Indeed, a transcriptomic study of the human colonic mucosa reported that butyrate stimulated the transcription of PDH, citrate synthase (TCA enzyme) and succinate dehydrogenase (respiratory chain) (52). Furthermore, using germ-free mice, Donohoe et al. (53) suggested that butyrate stimulates mitochondrial oxidation of glucose in colonic epithelial cells. Interestingly, Moretti et al. (9) showed that sodium butyrate treatment in a rat model of mania modified mitochondrial function in prefrontal cortex, hippocampus, amygdala and striatum. Therefore, our data could suggest that increasing colonic production of butyrate, for example with fibre-enriched diets, could influence brain glucose metabolism.

The dorsal and ventral parts of the hippocampus are two functionally different structures that are connected to different neuronal networks (54). The dorsal hippocampus performs primarily cognitive functions whereas the ventral hippocampus relates to stress, emotions and affect. For example in rats, lesions in the dorsal hippocampus caused spatial memory impairment in the radial arm maze, contrary to lesions in the ventral hippocampus (55), and stress-related genes were found expressed in the ventral hippocampus of prenatally stressed rats (56). Interestingly, ventral hippocampal afferents to the nucleus accumbens were also found regulating susceptibility to depression (57). If the changes of regional metabolism in the nucleus accumbens and hippocampus further to butyrate supplementation were confirmed in a pig model of anxiety/depression, early malnutrition, or neurocognitive alterations, then behavioral tests might reveal whether these brain modulations are accompanied by changes in cognitive abilities and susceptibility to stress or anxiety. Interestingly, we previously demonstrated that perinatal administration of butyrate to dams improved performance in the spatial memory test on young rats that visited more frequently the novel arm during a Y-maze test (58). Gieling et al. (59) reviewed studies in pig cognition...
and identified several promising types of tasks such as versatile spatial free-choice type tasks allowing for simultaneous measurement of several behavioural domains. In a recent study, we showed that piglets with unbalanced perinatal nutrition had smaller hippocampal granular cell layer and decreased neurogenesis, as well as different cognitive responses compared to control animals during a spatial memorization and learning task (38). These pig models might be valuable to assess whether butyrate supplementation could reverse the deleterious neurocognitive and emotional effects of early malnutrition and/or mental pathologies.

The growing pigs used in our study were approximately 2 month-old at the beginning of the experiment. It is therefore likely that their brain functions and metabolism were still subject to plasticity mechanisms, and that their brain did not completely switch from monocarboxylates consumption during the early postnatal period to glucose consumption later on. Chronic ingestion of sodium butyrate might modify the circulating levels of monocarboxylates, including butyrate and lactate. This could explain the decreased plasma lactate levels in SB pigs just before brain imaging, and the fact that plasma lactate levels were lower in SB than C pigs. In the hypothesis of an increased passage of butyrate and perhaps lactate to the brain, the question of their interaction or competition with glucose can be raised.

The radioligand used in our study to investigate regional brain metabolism was a glucose analogue (\(^{18}\)F-FDG) that is uptaken by brain cells, including glial cells and neurons. This exogenous glucose competes with endogenous glucose. Aside from the conventional view of brain energy metabolism stating that glucose is consumed preferentially in neurons (22), an alternative model suggests that glucose preferentially taken by astrocytes, is degraded to lactate and then exported into neurons to be oxidized (60). Facing such a complex situation, the only conclusion we can draw up upon our own results is that chronic consumption of sodium butyrate during three weeks was sufficient to decrease basal plasma lactate levels and modify the regional glucose metabolism in the hippocampus and nucleus accumbens.
Our data indicate that a 4-week period of sodium butyrate intake impacted very little gut anatomy and function. Indeed, this treatment only tended to reduce gut secretory capacity and trans-cellular permeability in basal condition and lowered amino-peptidase N total activity in the jejunum. By contrast, neither villus-crypt architecture nor para-cellular permeability and inducible HSPs were affected. This is in contrast with our previous investigations in piglets and calves (12, 13), possibly because in this experiment, the pigs were older and heavier than previously. Based on the gut variables measured in the present experiment, this organ appears to contribute very little to the effects of butyrate observed at the brain level, but further explorations are needed to see whether butyrate might modulate other gastrointestinal tract parameters than those investigated in this study, and consequently send information to the brain to modulate its metabolism and plasticity. For example, peripheral and central immunity might be explored, as well as inflammation markers at both levels.

In conclusion, this study demonstrated that oral sodium butyrate influences regional brain metabolism and plasticity, and that the gut, systemic glucose control, or gut hormones variations appear to contribute very little to these effects. Further studies are needed to determine whether the butyrate effects on brain metabolism and hippocampal plasticity can improve neurocognition and mental welfare, especially when brain and behavioural disorders are observed. Different pig models are already available to investigate this question in the context of early malnutrition or diet-induced conditions. This would pave the way to a new treatment against nutritional- or stress-related psychological disorders.

Acknowledgements

This study was part of a research project (EPIMEMO) funded by Région Pays de la Loire and coordinated by Jean-Pierre Segain and Patricia Parnet. The authors gratefully
acknowledge the efforts and cooperation of the technical staff, and especially Alain Chauvin and Francis Legouevec for participating in this study and taking care of the animals.

References


Table 1. Brain structures presenting a higher (SB > C) or lower (SB < C) glucose metabolism (expressed in Standard Uptake Value) in butyrate-supplemented piglets (SB group) compared to control piglets (C group) using a “without a priori” first-level global analysis and a “with a priori” second-level small volume correction (SVC) analysis. The SVC analysis included the following regions of interest (ROI): anterior prefrontal cortex, dorsolateral prefrontal cortex, orbitofrontal cortex, cingulate cortex, hippocampus, parahippocampal cortex, amygdala, caudate, putamen, nucleus accumbens, globus pallidus. The peak t-value, uncorrected P-value and coordinates in the CA-CP (comissura anterior-commissura posterior) reference plane are indicated for each significant cluster comprising at least 25 voxels, for the left (L) and/or right (R) hemispheres.

<table>
<thead>
<tr>
<th>Brain structures</th>
<th>Side</th>
<th>Peak t</th>
<th>Peak P(unc)</th>
<th>x,y,z</th>
<th>Peak t</th>
<th>Peak P(unc)</th>
<th>x,y,z</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First-level global analysis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary somatosensory cortex</td>
<td>L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R</td>
<td>4.39</td>
<td>&lt;0.001</td>
<td>8 15 25</td>
<td>3.13</td>
<td>0.004</td>
<td>-26 5 6</td>
</tr>
<tr>
<td>Inferior temporal gyrus</td>
<td>L</td>
<td>3.38</td>
<td>0.002</td>
<td>-8 -8 -2</td>
<td>3.35</td>
<td>0.003</td>
<td>12 3 -3</td>
</tr>
<tr>
<td>Inferior colliculus</td>
<td>L</td>
<td>3.38</td>
<td>0.002</td>
<td>-8 -8 -2</td>
<td>3.35</td>
<td>0.003</td>
<td>12 3 -3</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>R</td>
<td>3.32</td>
<td>0.003</td>
<td>12 3 -4</td>
<td>2.67</td>
<td>0.010</td>
<td>10 -2 9</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>R</td>
<td>2.66</td>
<td>0.010</td>
<td>10 -2 9</td>
<td>2.66</td>
<td>0.010</td>
<td>10 -2 9</td>
</tr>
</tbody>
</table>

529
Table 2. Gut electrophysiology parameters determined *ex vivo* in Ussing chambers (n=6-8 per treatment).

<table>
<thead>
<tr>
<th>Site</th>
<th>Treatments²</th>
<th>Jejunum</th>
<th>Ileum</th>
<th>Colon</th>
<th>Statistics (P=)¹</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C</td>
<td>SB</td>
<td>C</td>
<td>SB</td>
<td>SEM</td>
</tr>
<tr>
<td>Dísc-glucose (µA/cm²)</td>
<td>47</td>
<td>70</td>
<td>37</td>
<td>25</td>
<td>62</td>
</tr>
<tr>
<td>TEER (Ω x cm²)</td>
<td>50</td>
<td>49</td>
<td>57</td>
<td>51</td>
<td>46</td>
</tr>
<tr>
<td>dIsc-glucose (µA/cm²)</td>
<td>8</td>
<td>11</td>
<td>17</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>dIsc-carbachol (µA/cm²)</td>
<td>21</td>
<td>14</td>
<td>32</td>
<td>5</td>
<td>51</td>
</tr>
</tbody>
</table>

**Under oxidant stress (monochloramine, MC)²**

| dIsc-MC (µA/cm²) | 5  | -55 | 6  | 5  | -44 | -115 | 36 | 0.29 | 0.19 | 0.63 |
| dIsc-glucose (µA/cm²) | 4.7 | 1.0 | 4.8 | 1.2 | 1.8 | 2.6 | 2.5 | 0.49 | 0.68 | 0.04 |
| dIsc-carbachol (µA/cm²) | 21 | 11 | 18 | 12 | 32 | 5  | 8  | 0.18 | 0.96 | 0.64 |

¹Tr.: Treatment; Tr.*Site: treatment by site interaction.
²Treatments: C: control; SB: sodium butyrate.
³Isc: short-circuit current; TEER: trans-epithelial electrical resistance; dIsc: variation in Isc (following glucose or carbachol or monochloramine addition).
Table 3. Influence of site and dietary treatment on gut para- and trans-cellular permeabilities determined ex vivo in Ussing chambers (log-transformed data; n=6-8 per treatment).

<table>
<thead>
<tr>
<th>Site</th>
<th>Jejunum</th>
<th>Ileum</th>
<th>Colon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatments</td>
<td>C</td>
<td>SB</td>
<td>C</td>
</tr>
<tr>
<td>FD4 (ng/cm²/h, log)</td>
<td>2.9</td>
<td>2.9</td>
<td>3.1</td>
</tr>
<tr>
<td>HRP (ng/cm²/h, log)</td>
<td>2.0</td>
<td>2.0</td>
<td>2.3</td>
</tr>
</tbody>
</table>

Under oxidant stress (monochloramine)

| Treatments   | C | SB | C | SB | C | SB |
| FD4 (ng/cm²/h, log) | 2.8 | 2.9 | 3.1 | 2.9 | 3.1 | 2.9 | 0.09 | 0.49 | 0.34 | 0.49 |
| HRP (ng/cm²/h, log)   | 1.9 | 2.0 | 2.2 | 2.1 | 2.4 | 2.0 | 0.17 | 0.70 | 0.52 | 0.22 |

1 Tr.: Treatment; Tr.*Site: treatment by site interaction.
2 Treatments: C: control; SB: sodium butyrate.
3 FD4: Fluorescein dextran 4000 (para-cellular permeability marker, 4 kDa); HRP: horseradish peroxidase (trans-cellular permeability marker, 40 kDa).
Table 4. Influence of dietary treatment on body weight, relative pancreas weight and protein concentration, and specific and total activities of the pancreatic enzymes (n=7-8 per treatment).

<table>
<thead>
<tr>
<th>Treatment</th>
<th>C</th>
<th>SB</th>
<th>SEM</th>
<th>Statistics (P=)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (Kg)</td>
<td>42.3</td>
<td>41.8</td>
<td>1.2</td>
<td>0.95</td>
</tr>
<tr>
<td>Fresh pancreas weight (mg/kg BW&lt;sup&gt;1&lt;/sup&gt;)</td>
<td>2.25</td>
<td>2.13</td>
<td>0.8</td>
<td>0.39</td>
</tr>
<tr>
<td>Pancreas protein</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mg/g fresh pancreas</td>
<td>207.7</td>
<td>201.5</td>
<td>12.6</td>
<td>0.77</td>
</tr>
<tr>
<td>mg/kg BW</td>
<td>468.2</td>
<td>431.8</td>
<td>37.4</td>
<td>0.88</td>
</tr>
<tr>
<td>Specific activities&lt;sup&gt;2&lt;/sup&gt; (/g fresh pancreas)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trypsin (IU)</td>
<td>444.3</td>
<td>404.2</td>
<td>35.6</td>
<td>0.89</td>
</tr>
<tr>
<td>Amylase (10&lt;sup&gt;-3&lt;/sup&gt;IU)</td>
<td>7.2</td>
<td>7.5</td>
<td>0.8</td>
<td>0.37</td>
</tr>
<tr>
<td>Lipase (10&lt;sup&gt;-3&lt;/sup&gt;IU/)</td>
<td>79.8</td>
<td>81.1</td>
<td>9.5</td>
<td>0.45</td>
</tr>
<tr>
<td>Relative activities&lt;sup&gt;2&lt;/sup&gt; (/kg BW&lt;sup&gt;1&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trypsin (10&lt;sup&gt;3&lt;/sup&gt;IU)</td>
<td>208.7</td>
<td>175.3</td>
<td>21.8</td>
<td>0.44</td>
</tr>
<tr>
<td>Amylase (IU)</td>
<td>32.8</td>
<td>33.1</td>
<td>4.4</td>
<td>0.52</td>
</tr>
<tr>
<td>Lipase (IU)</td>
<td>38.0</td>
<td>34.2</td>
<td>5.8</td>
<td>0.69</td>
</tr>
</tbody>
</table>

<sup>1</sup> Body weight.

<sup>2</sup> IU = mmol substrate hydrolyzed/min.
Table 5. Influence of site and dietary treatment on enzyme activities along the gut (n=7-8 per treatment).

<table>
<thead>
<tr>
<th>Site</th>
<th>Duodenum</th>
<th>Jejunum</th>
<th>Ileum</th>
<th>Colon</th>
<th>Statistics (P =)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C</td>
<td>SB</td>
<td>C</td>
<td>SB</td>
<td>C</td>
</tr>
<tr>
<td>Peptidases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APN (SA)3,4</td>
<td>55</td>
<td>48</td>
<td>201</td>
<td>159</td>
<td>136</td>
</tr>
<tr>
<td>APN (TA)3,4</td>
<td>5.7</td>
<td>5.4</td>
<td>19.5a</td>
<td>14.8b</td>
<td>13.4</td>
</tr>
<tr>
<td>DPP4 (SA)</td>
<td>26</td>
<td>25</td>
<td>26</td>
<td>21</td>
<td>12</td>
</tr>
<tr>
<td>DPP4 (TA)</td>
<td>2.9</td>
<td>2.9</td>
<td>2.9</td>
<td>2.4</td>
<td>1.4</td>
</tr>
<tr>
<td>Disaccharidases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sucrase (SA)</td>
<td>15</td>
<td>11</td>
<td>115</td>
<td>90</td>
<td>35</td>
</tr>
<tr>
<td>Sucrase (TA)</td>
<td>1.5</td>
<td>1.3</td>
<td>11.1</td>
<td>8.9</td>
<td>3.3</td>
</tr>
<tr>
<td>Maltase (SA)</td>
<td>84</td>
<td>78</td>
<td>334</td>
<td>282</td>
<td>129</td>
</tr>
<tr>
<td>Maltase (TA)</td>
<td>9.0</td>
<td>8.9</td>
<td>32.6</td>
<td>27.6</td>
<td>12.1</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IAP (SAC)3,4</td>
<td>1.5</td>
<td>2.1</td>
<td>3.4</td>
<td>2.9</td>
<td>3.5</td>
</tr>
<tr>
<td>IAP (TAC)3,4</td>
<td>105</td>
<td>143</td>
<td>229</td>
<td>169</td>
<td>210</td>
</tr>
</tbody>
</table>

1 Tr.: Treatment; Tr.*Site: treatment by site interaction.
2 Treatments: C: control; SB: sodium butyrate.
3 APN: amino-peptidase N; DPP4: dipeptidyl-peptidase 4; IAP: intestinal alkaline phosphatase.
4 SA: Specific activity (µmoles/min/mg protein; nmoles/min/mg protein for DPP4); SAC: Specific activity concentration for IAP (µg IAP/ g protein). TA: total activity (µmoles/min/g fresh mucosa; nmoles/min/g fresh mucosa for DPP4); TAC: Total activity concentration for IAP (µg IAP/ g fresh tissue).

ab P < 0.05
**Fig 1.** Changes in plasma concentrations of (A) lactate, (B) PYY and (C) GLP-1 before and after drinking the beverages (both groups merged: pigs received either pure water (control) or sodium butyrate-supplemented beverage). (D) Differences in plasma osmolality between groups and sampling time. (E) Plasma lactate concentration a week later, just before brain imaging.

**Fig 2.** Sagittal and axial magnetic resonance imaging models and sections showing the main brain structures of differential glucose metabolism identified during the statistical parametric mapping (SPM) analysis for the contrast butyrate vs. control. A) Three-dimensional brain models showing the whole structures of interest. B) Magnetic resonance imaging sections showing the significant clusters of brain activation or deactivation. The x or y coordinates in the *commissura anterior-commissura posterior* (CA-CP) plane are indicated below the images. The statistical threshold was set at $P < 0.01$ (uncorrected). Red spots indicate a glucose metabolism higher in SB group compared to C group. Blue spots indicate a glucose metabolism lower in SB group compared to C group. HIP: hippocampus; NAc: nucleus accumbens; ISSC: primary somatosensory cortex.

**Fig 3.** Hippocampal and granular cell layer (GCL) volume determination along the hippocampus sections. A) Representative view of 10 sections covering the first 7.5 mm of hippocampus. B) Calculated block volume for each site. The presented values are considering the entire block of 25 sections of 30 µm each, and give an insight of the overall volume of the hippocampus and the GCL. Significant difference between treatments was found for GCL volume only. Data are presented as mean ± SEM.
Fig 4. Hippocampal structural plasticity. A) Immunostaining of brain sections showing Ki67-positive nucleus distribution (left) and DCX-positive (doublecortin, right) cells within the granular cell layer (GCL) of the hippocampus. B) Quantification of Ki67-positive nucleus in the sub granular zone (SGZ, left) and DCX-positive cells in the GCL along the hippocampus. The presented values are considering the entire block of 25 sections of 30 µm for each histological slice. Significant differences were found between dietary treatments for Ki67 and DCX. Data are presented as mean ± SEM. An asterisk indicates a significant difference at P<0.05.